eGenesis attracts $38 mln Series A
Cambridge, Massachusetts-based eGenesis, a biotechnology company, has raised $38 million in Series A financing. Biomatics Capital and ARCH Venture Partners led the round with participation from Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America Ltd, Uprising, and Fan Ventures. In conjunction with the funding, Daniel S. Lynch was appointed executive chairman of eGenesis.
16 March 2017•1 min read
